ArticleScience (New York, N.Y.)2021
Replication and single-cycle delivery of SARS-CoV-2 replicons.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 82 citations in OpenAlex.
- Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers.Molecular therapy. Nucleic acids · 2026Article
- Identification of (20R)-protopanaxadiol from Panax ginseng as a novel anti-SARS-CoV-2 compound.FEBS open bio · 2026Article
- Evaluation of a proposed link between the SARS-CoV-2 furin cleavage site and mouse-adapted MERS-coronavirus MA30.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- SARS-CoV-2 enhances lysosomal exocytosis and deacidifies lysosomes to facilitate viral release.mLife · 2026Article
- Article
- SARS-CoV-2-host and interactions: the dual roles of E3 ubiquitin ligases and ubiquitin-like modification mechanisms in viral infection.Frontiers in immunology · 2026Review
- Article
- SARS-CoV-2 reshapes mNAR molecular medicine · 2025Article
- A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening.Viruses · 2025Article
- SARS-CoV-2 NSP3/4 control formation of replication organelle and recruitment of RNA polymerase NSP12.The Journal of cell biology · 2025Article
- Advances in the development of infectious clones of human coronaviruses and related applications.Biosafety and health · 2025Review
- Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection.JCI insight · 2025Article
- SARS-CoV-2 specific adaptations in N protein inhibit NF-κB activation and alter pathogenesis.The Journal of cell biology · 2025Article
- Catch me if you can: viral nucleic acids to host sensors.Frontiers in immunology · 2025Review
- Review
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.PLoS pathogens · 2024Article
- SARS-CoV-2 evolution balances conflicting roles of N protein phosphorylation.PLoS pathogens · 2024Article
- A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.PLoS biology · 2024Article
- A BSL-2 compliant mouse model of SARS-CoV-2 infection for efficient and convenient antiviral evaluation.Journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 2 countries.
Inna Ricardo-Lax *Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-9590-9692
Joseph M Luna *Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-2415-9203
Tran Thi Nhu ThaoInstitute of Virology and Immunology (IVI), Bern, Switzerland.
Jérémie Le PenLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-7025-9526
Yingpu YuLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-4837-5744
H-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-0554-0244
William M SchneiderLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-9407-6118
Brandon S RazookyLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-5263-1512
Javier Fernandez-MartinezLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-0567-498X
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-7731-6685
Yiska WeisblumLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-9249-1745
Bettina Salome TrüebInstitute of Virology and Immunology (IVI), Bern, Switzerland.
Inês Berenguer VeigaInstitute of Virology and Immunology (IVI), Bern, Switzerland.ORCID 0000-0001-8554-790X
Kimberly SchmiedInstitute of Virology and Immunology (IVI), Bern, Switzerland.ORCID 0000-0002-6158-7074
Nadine EbertInstitute of Virology and Immunology (IVI), Bern, Switzerland.
Eleftherios MichailidisLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-9907-4346
Avery PeaceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-3074-1662
Francisco J Sánchez-RiveraCancer Biology and Genetics, MSKCC, New York, NY 10065, USA.ORCID 0000-0002-8466-8563
Scott W LoweCancer Biology and Genetics, MSKCC, New York, NY 10065, USA.ORCID 0000-0002-5284-9650
Michael P RoutLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
John T PoirierLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA.ORCID 0000-0001-9795-5644
Margaret R MacDonaldLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-5177-2068
Volker ThielInstitute of Virology and Immunology (IVI), Bern, Switzerland.ORCID 0000-0002-5783-0887
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-3087-8079
Rockefeller University · USUniversity of Bern · CHMemorial Sloan Kettering Cancer Center · USNew York University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0MTR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8MVirology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2018 to 2022
$8.4MUnraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunityR01AI124690 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2016 to 2026
$8.3MType I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5MLaunching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biologyR01AI150275 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2020 to 2026
$4.4MA systematic analysis of small RNA interactions during RNA virus infectionsR01AI116943 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2016 to 2020
$3.0MIn search of an HBV cure: novel model systems and targetsR01AI143295 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2019 to 2023
$3.0MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MThe impact of chromosome 17p lesions on leukemogeneis and therapy responseR01CA190261 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W. · 2015 to 2019
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA190261NCI NIH HHS T32 CA160001NCI NIH HHS U01 CA213359NIAID NIH HHS P01 AI138938NIAID NIH HHS R01 AI091707NIAID NIH HHS R01 AI116943NIAID NIH HHS R01 AI124690NIAID NIH HHS R01 AI143295NIAID NIH HHS R01 AI150275NIAID NIH HHS R03 AI141855NIAID NIH HHS R21 AI142010NIAID NIH HHS U19 AI111825NIGMS NIH HHS P41 GM109824
Abstract
Molecular virology tools are critical for basic studies of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental systems that do not rely on viruses capable of spread are needed for potential use in lower-containment settings. In this work, we use a yeast-based reverse genetics system to develop spike-deleted SARS-CoV-2 self-replicating RNAs. These noninfectious self-replicating RNAs, or replicons, can be trans-complemented with viral glycoproteins to generate replicon delivery particles for single-cycle delivery into a range of cell types. This SARS-CoV-2 replicon system represents a convenient and versatile platform for antiviral drug screening, neutralization assays, host factor validation, and viral variant characterization.
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsCell LineHumansInterferonsMicrobial Sensitivity TestsMutationPlasmidsRepliconReverse GeneticsRNA, ViralSaccharomyces cerevisiaeSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsInterferonsORF1ab polyprotein, SARS-CoV-2RNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Nonstructural Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.